These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27122156)

  • 1. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
    González-Perera I; Gutiérrez-Nicolás F; Nazco-Casariego GJ; Ramos-Díaz R; Hernández-San Gil R; Pérez-Pérez JA; González García J; González De La Fuente GA
    J Oncol Pharm Pract; 2017 Jul; 23(5):396-398. PubMed ID: 27122156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPYD variants to predict 5-FU toxicity: the ultimate proof.
    Innocenti F
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381394
    [No Abstract]   [Full Text] [Related]  

  • 3. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
    Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
    Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
    PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
    Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Grothey A; Polite B; Chan E; Gill S; Kahlenberg MS; Nair SG; Shields AF; Goldberg RM; Diasio RB
    Pharmacogenet Genomics; 2016 Mar; 26(3):133-7. PubMed ID: 26658227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
    Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
    Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
    Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
    Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
    Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
    Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
    Negarandeh R; Salehifar E; Saghafi F; Jalali H; Janbabaei G; Abdhaghighi MJ; Nosrati A
    BMC Cancer; 2020 Jun; 20(1):560. PubMed ID: 32546132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
    Mounier-Boutoille H; Boisdron-Celle M; Cauchin E; Galmiche JP; Morel A; Gamelin E; Matysiak-Budnik T
    Br J Clin Pharmacol; 2010 Aug; 70(2):280-3. PubMed ID: 20653683
    [No Abstract]   [Full Text] [Related]  

  • 19. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.